United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - estriol - vaginal cream - 100microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - estriol - vaginal cream - 100microgram/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; disodium edetate; purified talc - this product accepted for registration as 'currently supplied' at the time of commencement of the act. variation to pregnancy statement in product information were approved as specified in the letter of 13 august 1992 from dr bijoy varma. indicated for the treatment of drug resistant, moderate to severe, hypertension. this drug is not a first line antihypertensive drug and is better used in combination with other therapy such as a sympatholytic agent and a diuretic. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

European Union - English - EMA (European Medicines Agency)

takeda manufacturing austria ag - c1 inhibitor (human) - angioedemas, hereditary - c1-inhibitor, plasma derived, drugs used in hereditary angioedema - treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (hae).routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of hereditary angioedema (hae), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

European Union - English - EMA (European Medicines Agency)

pharming group n.v. - recombinant human c1-inhibitor - angioedemas, hereditary - drugs used in hereditary angioedema, other hematological agents - ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (hae) due to c1-esterase-inhibitor deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; sodium chloride; sodium hydroxide; water for injections; hydrochloric acid; zinc; metacresol; dibasic sodium phosphate dihydrate; glycerol - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: phenol; zinc; dibasic sodium phosphate dihydrate; sodium hydroxide; glycerol; metacresol; sodium chloride; water for injections; hydrochloric acid - treatment of diabetes mellitus.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - insulin aspart, quantity: 100 u/ml - injection, solution - excipient ingredients: water for injections; metacresol; glycerol; sodium chloride; dibasic sodium phosphate dihydrate; hydrochloric acid; sodium hydroxide; zinc; phenol - treatment of diabetes mellitus.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - eflornithine hydrochloride (unii: 4nh22ndw9h) (eflornithine - unii:zqn1g5v6sr) - eflornithine hydrochloride anhydrous 139 mg in 1 g - vaniqa (eflornithine hydrochloride) cream, 13.9% is indicated for the reduction of unwanted facial hair in women. vaniqa has only been studied on the face and adjacent involved areas under the chin of affected individuals. usage should be limited to these areas of involvement. vaniqa is contraindicated in patients with a history of sensitivity to any components of the preparation.

United States - English - NLM (National Library of Medicine)

allergan, inc. - eflornithine hydrochloride (unii: 4nh22ndw9h) (eflornithine - unii:zqn1g5v6sr) - eflornithine hydrochloride anhydrous 139 mg in 1 g - vaniqa ®   (eflornithine hydrochloride) cream, 13.9% is indicated for the reduction of unwanted facial hair in women. vaniqa ® has only been studied on the face and adjacent involved areas under the chin of affected individuals. usage should be limited to these areas of involvement. vaniqa ® is contraindicated in patients with a history of sensitivity to any components of the preparation.